St. John's wort shows up in a lot of medicine cabinets as a mood support supplement, and it shows up in a lot of questions from employees who are worried a pre employment or random screen will flag it. The short answer is that St. John's wort is not a controlled substance, it is not a target analyte on any standard workplace drug test panel, and there is no credible published evidence that it cross reacts with the immunoassay screens used for amphetamines, cannabinoids, opiates, cocaine, PCP, or benzodiazepines. The real issue with this supplement has nothing to do with false positives. It has to do with drug interactions, and that matters a great deal for anyone in a medication assisted treatment program or taking a long term prescription.
What a standard workplace panel actually screens for
A typical 5 panel, 9 panel, or 12 panel workplace drug test is built around an immunoassay that is calibrated to react with a specific target drug class and its close chemical relatives. The classes are amphetamines, cannabinoids (THC), cocaine metabolites, opiates, PCP, and often benzodiazepines, barbiturates, methadone, and a few others depending on the panel. Hypericum perforatum, the plant St. John's wort comes from, and its active compounds hyperforin and hypericin, are not structurally related to any of those target classes. The National Center for Complementary and Integrative Health notes that herbal products like this one are marketed as dietary supplements under a regulatory path that is different from prescription or over the counter drugs, and dietary supplements are not reviewed and approved by the FDA before they reach store shelves. That regulatory status is part of why St. John's wort is not built into any standard immunoassay calibration, and it is also why there is no published research showing it produces a false positive on a workplace screen.
Screening immunoassay versus confirmation testing
Workplace drug testing is a two step process, and understanding the second step is the real answer to "could this cause a problem." The first step is an immunoassay screen run against a cutoff concentration. If a specimen screens positive, a certified laboratory runs a confirmatory test on a separate portion of the same specimen, using gas chromatography or liquid chromatography paired with mass spectrometry, which identifies and quantifies the specific drug or metabolite rather than reacting to a family of similar molecules. Federal testing regulations define a confirmatory drug test as a second analytical procedure performed to identify and quantify a specific drug or drug metabolite, and the same regulation sets a cross reactivity threshold that an immunoassay must meet before a related analyte can even be grouped into the same test. St. John's wort has no documented cross reactivity with any of the grouped analytes on a standard panel, which is why the honest, accurate statement is that there is no credible cross reactivity evidence, not that the supplement has been specifically tested and cleared against every immunoassay on the market.
The real concern is drug interactions, not false positives
St. John's wort has a well documented habit of changing how the body processes other medications. According to the National Center for Complementary and Integrative Health, it can weaken the effects of many medicines, including some antidepressants, birth control pills, cyclosporine used to prevent organ transplant rejection, seizure medications such as phenytoin and carbamazepine, some heart medications, blood thinners, and certain statins. Combining it with antidepressants or other drugs that affect serotonin can also raise the risk of serious serotonin related side effects. None of this changes what shows up on an immunoassay screen. It changes how much of a person's actual prescribed medication is circulating in their body, which is exactly the kind of thing a prescriber needs to know about and exactly the kind of thing that matters when steady, predictable medication levels are the point of treatment.
That is especially true for anyone in a medication assisted treatment program. SAMHSA's overview of medications for substance use disorders describes how these programs rely on maintaining consistent, monitored medication levels as part of treatment and recovery. A supplement that can lower blood levels of other prescribed drugs is a legitimate disclosure item for a prescriber or treatment team to know about, not because it will change a screening result, but because it can change how well a maintenance medication is working. This is a conversation for a doctor or pharmacist, never a do it yourself adjustment, and never a reason to stop or change a prescribed dose without medical guidance.
Where supplement disclosure belongs: the MRO process
When a workplace specimen screens positive and is confirmed by the laboratory, a medical review officer, a licensed physician trained in this specific role, contacts the employee directly and confidentially before any result reaches the employer. Federal drug testing regulations describe this as the MRO's duty to determine whether there is a legitimate medical explanation for a confirmed result, and SAMHSA maintains a Medical Review Officer Manual and related resources as part of its Drug-Free Workplace Programs guidance for federal agencies and regulated employers. This confidential interview is the right place to mention current prescriptions, and if it is relevant to the specific result in question, supplement use. It is not information an employer should ask about directly, and a supplement like St. John's wort, which is not a panel target to begin with, generally will not be part of that conversation at all unless it is tied to a confirmed result involving an actual prescribed medication the employee is taking alongside it.
Employers who manage their own drug free workplace policy may want to review the supply side of testing as well. Programs that rely on immunoassay cups or dip cards benefit from checking DailyMed, the National Library of Medicine's repository of current current prescribing information, when an employee or applicant raises a specific medication question, rather than relying on informal lists that can go out of date.
Supplements employees commonly ask about
| Supplement | Marketed for | Target on a standard immunoassay panel | Documented concern |
|---|---|---|---|
| St. John's wort (Hypericum perforatum) | Mood support | No | Can weaken the effect of many prescription drugs and raise serotonin risk with serotonergic medications |
| Melatonin | Sleep support | No | Not a panel target, generally considered low interaction risk, still worth mentioning to a prescriber |
| Biotin | Hair, skin, nail support | No | Not a drug test target, has been linked to inaccurate results on some unrelated lab blood assays at high doses |
| Creatine | Exercise performance | No, but affects specimen chemistry | Raises urine creatinine, a specimen validity marker, which is unrelated to any drug class result |
| Valerian root | Sleep and relaxation | No | Sedating, can add to the effect of other central nervous system depressants |
What employers should and should not do
An employer does not need to screen applicants or employees for supplement use, and should not build a policy that asks about supplements as a stand in for a medical inquiry. Supplement and prescription disclosure belongs with the MRO, confidentially, and only when it is relevant to a specific confirmed result. An employer may be able to require a confirmed positive result to go through standard MRO review like any other result, and should rely on that review rather than trying to interpret interactions or herbal product claims in house. A written drug free workplace policy, a consistent panel, and a clear path to MRO review for every confirmed result will cover a case like this correctly without turning a supplement question into a medical determination the employer is not positioned to make.
For programs building or refreshing a testing policy, a reliable, currently calibrated drug test cup paired with a defined confirmation and MRO process is the practical foundation. Related reading on specimen validity and supplement questions is available on our melatonin and drug test panels post, and a full walkthrough of what happens after a confirmed result is in our Medical Review Officer process guide.
Frequently asked questions
Does St. John's wort show up on a drug test?
No. It is not a target analyte on standard workplace immunoassay panels and there is no published cross reactivity evidence showing it triggers a positive screen.
Is St. John's wort a controlled substance?
No. It is sold as an herbal dietary supplement, which follows a different regulatory path than prescription or controlled drugs and is not reviewed and approved by the FDA before sale.
Why does St. John's wort matter for someone in a medication assisted treatment program?
It can lower blood levels of other medications a person is taking, which can affect how well a maintenance medication works. This is a question for a prescriber or treatment team, not something a specimen screen would detect.
Should an employee tell the medical review officer about supplement use?
If a confirmed result involves a prescribed medication and the employee is also taking a supplement that could affect it, that is appropriate information to share confidentially with the MRO. Supplements that are not involved in the confirmed result generally are not relevant to that conversation.
Can an employer ask applicants about supplement use?
Employers generally should not use supplement questions as a substitute for the confidential MRO process, and should direct any medication or supplement related discussion to that review rather than asking directly.
What is the difference between a screening test and a confirmation test?
A screening immunoassay flags specimens at or above a cutoff level for a drug class. A confirmation test uses gas chromatography or liquid chromatography with mass spectrometry on a separate portion of the specimen to identify and quantify the specific substance before a result is reported as positive.
This article is general information for employers and employees about workplace drug testing. It is not medical or legal advice. Anyone with questions about a specific medication, supplement, or confirmed test result should talk to a licensed physician, pharmacist, or the medical review officer handling that result.